Developing novel targeted radiopharmaceuticals for cancer treatment
Listen now
Description
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Manfred Ruediger, CEO of Ariceum Therapeutics. Ariceum Therapeutics is focused on developing novel targeted radiopharmaceuticals for the treatment of cancer. 2023 was a pivotal year for the company from a strategic perspective, including a €22.75 million Series A extension in April 2023, a strategic research collaboration with UCB in May 2023, and the acquisition of Theragnostics in June 2023. It was also named Winner of Deal of the Year Ruediger talks about the future for the company and its therapeutic pipeline.  Listen now. 
More Episodes
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company...
Published 04/29/24
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The leading news story this week has been the launch of a new clinical trial in the...
Published 04/29/24